[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635341":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":375,"collaborators":20,"id":377,"slug":378,"hasResults":379,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":20,"eligibilityCriteria":383,"healthyVolunteers":379,"sex":384,"minAge":385,"maxAge":20,"enrollmentInfo":386,"targetDuration":20,"studyType":389,"phases":390,"briefSummary":392,"conditions":393,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":404},{"fullName":5,"class":6},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TQ05105 Tablets","EXPERIMENTAL","TQ05105 Tablets, 28 days as a treatment cycle.",[13],"Drug: TQ05105 Tablets (Rovadicitinib Tablets)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","TQ05105 Tablets (Rovadicitinib Tablets)","TQ05105 is an inhibitor of Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing protein kinase 1 (ROCK1) and 2 (ROCK2).",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Chunkang Chang, Doctor","CONTACT","13764643870","changchunkang7010@aliyun.com",[28,47,62,77,92,107,121,135,149,164,179,189,204,219,233,248,263,278,288,300,315,330,345,360],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"The First Affiliated Hospital of University of Science and Technology of China","RECRUITING","Hefei","Anhui","230001","China","CN",{"type":37,"coordinates":38},"Point",[39,40],117.28083,31.86389,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":45,"phoneExt":20,"email":46},"Xiaoyu Zhu, Doctor","15255456091","xiaoyuz@ustc.edu.cn",{"facility":48,"status":30,"city":49,"state":50,"zip":51,"country":34,"countryCode":35,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Fujian Medical University Union Hospital","Fuzhou","Fujian","350001",{"type":37,"coordinates":53},[54,55],119.30611,26.06139,{"lat":55,"lon":54},[58],{"name":59,"role":24,"phone":60,"phoneExt":20,"email":61},"Yong Wu, Doctor","13365910911","wuyong9195@126.com",{"facility":63,"status":30,"city":64,"state":65,"zip":66,"country":34,"countryCode":35,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Guangzhou First Municipal People's Hospital","Guangzhou","Guangdong","510180",{"type":37,"coordinates":68},[69,70],113.25,23.11667,{"lat":70,"lon":69},[73],{"name":74,"role":24,"phone":75,"phoneExt":20,"email":76},"Shunqing Wang, Doctor","13437807998","drwangshq@medmail.com.cn",{"facility":78,"status":30,"city":79,"state":80,"zip":81,"country":34,"countryCode":35,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"The First Affiliated Hospital of Guangxi Medical University","Nanning","Guangxi","530000",{"type":37,"coordinates":83},[84,85],108.31667,22.81667,{"lat":85,"lon":84},[88],{"name":89,"role":24,"phone":90,"phoneExt":20,"email":91},"Zhenfang Liu, Doctor","13481082237","liuliuzhenfang@163.com",{"facility":93,"status":30,"city":94,"state":95,"zip":96,"country":34,"countryCode":35,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Cangzhou People's Hospital rovince","Cangzhou","Hebei","061014",{"type":37,"coordinates":98},[99,100],116.85334,38.31124,{"lat":100,"lon":99},[103],{"name":104,"role":24,"phone":105,"phoneExt":20,"email":106},"Hongmei Ma, Master","18031798229","mhm-sspc@163.com",{"facility":108,"status":30,"city":109,"state":95,"zip":110,"country":34,"countryCode":35,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Affiliated Hospital of Chengde Medical College","Chengde","067000",{"type":37,"coordinates":112},[113,114],117.95883,40.9519,{"lat":114,"lon":113},[117],{"name":118,"role":24,"phone":119,"phoneExt":20,"email":120},"Zhihua Zhang, Master","15633142905","zzhangzhihua@163.com",{"facility":122,"status":30,"city":123,"state":95,"zip":124,"country":34,"countryCode":35,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"The Second Hospital of Hebei Medical University","Shijiazhuang","050000",{"type":37,"coordinates":126},[127,128],114.47861,38.04139,{"lat":128,"lon":127},[131],{"name":132,"role":24,"phone":133,"phoneExt":20,"email":134},"Xuejun Zhang, Doctor","13722781112","zhxjhbmu@126.com",{"facility":136,"status":30,"city":137,"state":95,"zip":138,"country":34,"countryCode":35,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Xingtai People's Hospital","Xingtai","054000",{"type":37,"coordinates":140},[141,142],114.49272,37.06217,{"lat":142,"lon":141},[145],{"name":146,"role":24,"phone":147,"phoneExt":20,"email":148},"Zongjiu Jiao, Master","18631921299","1449569258@qq.com",{"facility":150,"status":30,"city":151,"state":152,"zip":153,"country":34,"countryCode":35,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Henan Cancer Hospital","Zhengzhou","Henan","450000",{"type":37,"coordinates":155},[156,157],113.64861,34.75778,{"lat":157,"lon":156},[160],{"name":161,"role":24,"phone":162,"phoneExt":20,"email":163},"Hu Zhou, Doctor","13939068863","papertigerhu@163.com",{"facility":165,"status":30,"city":166,"state":167,"zip":168,"country":34,"countryCode":35,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology","Wuhan","Hubei","430071",{"type":37,"coordinates":170},[171,172],114.26667,30.58333,{"lat":172,"lon":171},[175],{"name":176,"role":24,"phone":177,"phoneExt":20,"email":178},"Zhenya Hong, Postdoctoral","13476158466","hongzhenya@sina.com",{"facility":180,"status":30,"city":166,"state":167,"zip":168,"country":34,"countryCode":35,"cosmosGeoPoint":181,"geoPoint":183,"contacts":184},"Union Hospital Tongji College Huazhong University of Science and Technology",{"type":37,"coordinates":182},[171,172],{"lat":172,"lon":171},[185],{"name":186,"role":24,"phone":187,"phoneExt":20,"email":188},"Min Zhang, Doctor","15871818568","Zhangmin35@aliyun.com",{"facility":190,"status":30,"city":191,"state":192,"zip":193,"country":34,"countryCode":35,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"Zhuzhou Central Hospital","Zhuzhou","Hunan","412000",{"type":37,"coordinates":195},[196,197],113.15,27.83333,{"lat":197,"lon":196},[200],{"name":201,"role":24,"phone":202,"phoneExt":20,"email":203},"Chanjuan Shen, Master","18973389928","shenchanjuan@163.com",{"facility":205,"status":30,"city":206,"state":207,"zip":208,"country":34,"countryCode":35,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"Nanjing Drum Tower Hospital","Nanjin","Jiangsu","210000",{"type":37,"coordinates":210},[211,212],121.74055,31.75772,{"lat":212,"lon":211},[215],{"name":216,"role":24,"phone":217,"phoneExt":20,"email":218},"Bing Chen, Doctor","13951806490","chenbinggcp@163.com",{"facility":220,"status":30,"city":221,"state":207,"zip":222,"country":34,"countryCode":35,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"Jiangsu Provincial Hospital of Traditional Chinese Medicine","Nanjing","210029",{"type":37,"coordinates":224},[225,226],118.77778,32.06167,{"lat":226,"lon":225},[229],{"name":230,"role":24,"phone":231,"phoneExt":20,"email":232},"Xuejun Zhu, Doctor","13505152806","zhuxj2@sina.com",{"facility":234,"status":30,"city":235,"state":236,"zip":237,"country":34,"countryCode":35,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"The First Hospital of Jilin University","Changchun","Jilin","130021",{"type":37,"coordinates":239},[240,241],125.32278,43.88,{"lat":241,"lon":240},[244],{"name":245,"role":24,"phone":246,"phoneExt":20,"email":247},"Sujun Gao, Doctor","15843073208","sujung1963@163.com",{"facility":249,"status":30,"city":250,"state":251,"zip":252,"country":34,"countryCode":35,"cosmosGeoPoint":253,"geoPoint":257,"contacts":258},"Shengjing Hospital Affiliated to China Medical University","Shenyang","Liaoning","110000",{"type":37,"coordinates":254},[255,256],123.43278,41.79222,{"lat":256,"lon":255},[259],{"name":260,"role":24,"phone":261,"phoneExt":20,"email":262},"Huihan Wang, Doctor","18940256966","wanghh@sj-hospital.org",{"facility":264,"status":30,"city":265,"state":266,"zip":267,"country":34,"countryCode":35,"cosmosGeoPoint":268,"geoPoint":272,"contacts":273},"The First Affiliated Hospital of Air Force Medical University","Xi'an","Shaanxi","710000",{"type":37,"coordinates":269},[270,271],108.92861,34.25833,{"lat":271,"lon":270},[274],{"name":275,"role":24,"phone":276,"phoneExt":20,"email":277},"Guangxun Gao, Doctor","13991907320","gaoguangxun@fmmu.edu.cn",{"facility":279,"status":30,"city":265,"state":266,"zip":267,"country":34,"countryCode":35,"cosmosGeoPoint":280,"geoPoint":282,"contacts":283},"The First Affiliated Hospital of Xi'an Jiaotong University",{"type":37,"coordinates":281},[270,271],{"lat":271,"lon":270},[284],{"name":285,"role":24,"phone":286,"phoneExt":20,"email":287},"Pengcheng He, Doctor","18991232609","hpec_gcp@163.com",{"facility":289,"status":30,"city":290,"state":291,"zip":292,"country":34,"countryCode":35,"cosmosGeoPoint":293,"geoPoint":297,"contacts":298},"Shanghai Sixth People's Hospital","Shanghai","Shanghai Municipality","200233",{"type":37,"coordinates":294},[295,296],121.45806,31.22222,{"lat":296,"lon":295},[299],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"facility":301,"status":30,"city":302,"state":303,"zip":304,"country":34,"countryCode":35,"cosmosGeoPoint":305,"geoPoint":309,"contacts":310},"Heping Hospital Affiliated To Changzhi Medical College","Changzhi","Shanxi","046000",{"type":37,"coordinates":306},[307,308],113.10528,36.18389,{"lat":308,"lon":307},[311],{"name":312,"role":24,"phone":313,"phoneExt":20,"email":314},"Xuliang Shen, Doctor","13015365546","shenxlcyp@sohu.com",{"facility":316,"status":30,"city":317,"state":318,"zip":319,"country":34,"countryCode":35,"cosmosGeoPoint":320,"geoPoint":324,"contacts":325},"Sichuan Provincial People's Hospital","Chengdu","Sichuan","610000",{"type":37,"coordinates":321},[322,323],104.06667,30.66667,{"lat":323,"lon":322},[326],{"name":327,"role":24,"phone":328,"phoneExt":20,"email":329},"Xiaobing Huang, Doctor","18981838236","hxb_trial@163.com",{"facility":331,"status":30,"city":332,"state":333,"zip":334,"country":34,"countryCode":35,"cosmosGeoPoint":335,"geoPoint":339,"contacts":340},"Chinese Academy of Medical Sciences Hematology Hospital","Tianjin","Tianjin Municipality","301617",{"type":37,"coordinates":336},[337,338],117.17667,39.14222,{"lat":338,"lon":337},[341],{"name":342,"role":24,"phone":343,"phoneExt":20,"email":344},"Bo Jiang, Doctor","18630810181","jiangbo@ihcams.as.cn",{"facility":346,"status":30,"city":347,"state":348,"zip":349,"country":34,"countryCode":35,"cosmosGeoPoint":350,"geoPoint":354,"contacts":355},"The First Affiliated Hospital of Xinjiang Medical University","Ürümqi","Xinjiang","830011",{"type":37,"coordinates":351},[352,353],87.60046,43.80096,{"lat":353,"lon":352},[356],{"name":357,"role":24,"phone":358,"phoneExt":20,"email":359},"Jianping Hao, Master","13579876416","13579876416@163.com",{"facility":361,"status":30,"city":362,"state":363,"zip":364,"country":34,"countryCode":35,"cosmosGeoPoint":365,"geoPoint":369,"contacts":370},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310003",{"type":37,"coordinates":366},[367,368],120.16142,30.29365,{"lat":368,"lon":367},[371],{"name":372,"role":24,"phone":373,"phoneExt":20,"email":374},"Hongyan Tong, Doctor","13958122357","hongyantong@aliyun.com",{"type":376,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100635341","phase-2-a-clinical-trial-to-evaluate-the-efficacy-safety-and-pharmacokinetics-of-tq05105-tablets-in-subjects-with-intermediatehigh-risk-myelofibrosis-100635341",false,"NCT07551427","A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate\u002FHigh-risk Myelofibrosis","A Phase II, Single-arm, Open-label, Multicenter Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate\u002FHigh-risk Myelofibrosis","Inclusion Criteria:\n\n1. Voluntary and signed informed consent, good compliance.\n2. Age ≥18 years (at time of signing informed consent); Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2; life expectancy ≥24 weeks.\n3. Diagnosis of primary myelofibrosis (PMF) per World Health Organization (WHO) 2016, or post-polycythemia vera myelofibrosis (post-PV-MF) or post-essential thrombocythemia myelofibrosis (post-ET-MF) per International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria; Janus kinase 2 (JAK2) mutation status not restricted.\n4. Intermediate or high risk per Dynamic International Prognostic Scoring System (DIPSS).\n5. Cohort 1: Renal function classified as normal, mild impairment, or moderate impairment. Cohort 2: Prior Janus kinase (JAK) inhibitor therapy with refractory, relapsed, or intolerant.\n6. Spleen enlargement (except Cohort 1).\n7. Peripheral blood and bone marrow blasts ≤10%.\n8. No growth factors, colony-stimulating factors, thrombopoietin, or platelet transfusion within 2 weeks before first dose; and routine blood parameters meet requirements within 7 days before first dose.\n9. Adequate major organ function within 7 days before first dose per protocol (renal function not restricted for Cohort 1).\n10. Agreement to use effective contraception during the study and for 6 months after; negative pregnancy test for females of childbearing potential; non-lactating.\n\nExclusion Criteria:\n\n1. Prior allogeneic stem cell transplantation, or autologous stem cell transplantation within 3 months before first dose, or planned stem cell transplantation.\n2. Prior treatment with 2 or more Janus kinase (JAK) inhibitors (except Cohort 1).\n3. Prior splenectomy or splenic radiotherapy within 6 months before first dose.\n4. Other malignancies within 3 years before first dose or currently present (exceptions per protocol).\n5. Factors affecting oral drug absorption.\n6. Non-hematologic toxicity from prior therapy not recovered to ≤ grade 1 (excluding hypertension and alopecia).\n7. Major surgery or significant traumatic injury within 4 weeks before first dose.\n8. Congenital bleeding or coagulation disorders.\n9. Arterial\u002Fvenous thrombosis event within 6 months before first dose.\n10. History of substance abuse or mental disorder.\n11. Active or uncontrolled severe infection.\n12. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n13. Grade ≥2 myocardial ischemia or infarction, arrhythmia, QT prolongation, or grade ≥2 congestive heart failure.\n14. Uncontrolled hypertension despite standard therapy.\n15. Renal failure requiring hemodialysis or peritoneal dialysis.\n16. Newly diagnosed pulmonary interstitial fibrosis or drug-related interstitial lung disease within 3 months before first dose.\n17. History of immunodeficiency or organ transplantation.\n18. Epilepsy requiring treatment.\n19. Use of protocol-prohibited myelofibrosis (MF) medications, immunomodulators, or immunosuppressants within specified time before first dose.\n20. Use of Chinese patent medicines with anti-tumor indications approved by National Medical Products Administration (NMPA) within 2 weeks before first dose.\n21. Uncontrolled pleural effusion, pericardial effusion, or ascites.\n22. Live attenuated vaccine within 4 weeks before first dose or planned during the study.\n23. Known hypersensitivity to study drug or excipients.\n24. Diagnosis of active autoimmune disease within 2 years before first dose.\n25. Participation in another interventional clinical trial with investigational drug within 4 weeks before first dose.\n26. Any condition that, in the investigator's judgment, seriously endangers subject safety or interferes with study completion.","ALL","18 Years",{"count":387,"type":388},51,"ESTIMATED","INTERVENTIONAL",[391],"PHASE2","This is an open-label, single-arm, multi-center phase II study consisting of two cohorts. Cohort 1 evaluates the pharmacokinetics (PK) of TQ05105 in myelofibrosis participants with normal, mild, or moderate renal impairment to guide dosing. Cohort 2 evaluates the efficacy and safety of TQ05105 in participants with intermediate\u002Fhigh-risk myelofibrosis who are refractory, relapsed, or intolerant to prior Janus kinase (JAK) inhibitor therapy.",[394],"Myelofibrosis","2026-07-14",{"date":397,"type":398},"2026-07-15","ACTUAL",{"date":400,"type":398},"2026-06-18",{"date":402,"type":388},"2029-06",{"name":5,"class":6},24]